DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 017557/S-033
NDA 017557/S-039
NDA 017557/S-040
NDA 017557/S-041
NDA 017557/S-042

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC
Attention: Katherine Ng
USRAMP – Base Business Product Support
55 Corporate Drive
Mall Stop 55C-205A
Bridgewater, NJ 08807-0912

Dear Ms. Ng:

Please refer to your Supplemental New Drug Applications (sNDAs) dated August 18, 1994, December 8, 2008, September 24, 2009, September 30, 2009, and May 5, 2010, received August 22, 1994, December 9, 2008, September 24, 2009, September 30, 2009, and May 5, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DANOCRINE® Brand of DANAZOL CAPSULES, USP.

We acknowledge receipt of your amendments dated June 3, 2009, September 23, 2009, and July 7, 2011.

These "Changes Being Effected" and "Prior Approval" supplemental new drug applications provide for or propose the following:

NDA 017557/S-033 was submitted on August 18, 1994 as a "Prior Approval" Supplement requesting revisions to the **CLINICAL PHARMACOLOGY** and **DOSAGE AND ADMINISTRATION** sections of the Package Insert.

NDA 017557/S-039 was submitted on December 8, 2008, as a "Changes Being Effected" supplement proposing revisions to the **WARNINGS** and **PRECAUTIONS** sections to include information regarding the risk of ovarian cancer in patients treated with Danocrine for endometriosis.

NDA 017557/S-040 was submitted on September 24, 2009, as a "Prior Approval Supplement" proposing language for Geriatric Use to be included in the **PRECAUTIONS** section of the Danocrine® Package Insert.

NDA 017557/S-041 was submitted September 30, 2009, as a "Changes Being Effected" supplement to include a safety change to the **PRECAUTIONS, Drug Interactions** subsection regarding increased risk of myopathy and rhabdomyolysis with concomitant administration of danazol with statins.

NDA 017557/S-042 was submitted May 5, 2010, to add in the **ADVERSE REACTIONS** section, "splenic peliosis."

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim Shiley, R.N., B.S.N., Regulatory Health Project Manager, at (301) 796-2117.

Sincerely,

{See appended electronic signature page}

Christine Nguyen, M.D.
Acting Deputy Director for Safety
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTINE P NGUYEN
12/20/2011